Featured Publications
An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis
Arab J, Sehrawat T, Simonetto D, Verma V, Feng D, Tang T, Dreyer K, Yan X, Daley W, Sanyal A, Chalasani N, Radaeva S, Yang L, Vargas H, Ibacache M, Gao B, Gores G, Malhi H, Kamath P, Shah V. An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis. Hepatology 2020, 72: 441-453. PMID: 31774566, PMCID: PMC7250715, DOI: 10.1002/hep.31046.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisSevere alcohol-associated hepatitisSerious adverse eventsMELD scoreDay 28Hepatic regenerationLille scoreAdverse eventsInterleukin-22Randomized placebo-controlled trialDose-escalating studyPlacebo-controlled trialDose-escalation studyMarkers of inflammationComparator cohortOpen labelFirst doseInflammatory markersSerum aminotransferasesSerum cytokinesEfficacy signalsSerum bilirubinMean agePatient cohortRegeneration markersXIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent in vitro and in vivo Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC
He L, Sehrawat T, Verma V, Navarro-Corcuera A, Sidhu G, Mauer A, Luo X, Katsumi T, Chen J, Shah S, Arab J, Cao S, Kashkar H, Gores G, Malhi H, Shah V. XIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent in vitro and in vivo Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC. Frontiers In Physiology 2021, 12: 664222. PMID: 34025452, PMCID: PMC8138467, DOI: 10.3389/fphys.2021.664222.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseLiver diseaseTreatment of ALDAggravated liver injuryAdvanced liver diseasePrimary hepatocytesBone marrow-derived macrophagesCaspase-3Marrow-derived macrophagesMechanisms of pathogenesisHuman liver tissueInflammatory markersInflammation markersLiver injuryCCl4 modelLiver steatosisClinical trialsCommon causeAnti-apoptotic proteinsKnockout micePeriportal regionHepatocyte apoptosisLiver tissueLow expressionALD model
2023
Adding Inflammatory Markers and Refining National Institute on Alcohol Abuse and Alcoholism Criteria Improve Diagnostic Accuracy for Alcohol-associated Hepatitis
Avitabile E, Díaz A, Montironi C, Pérez-Guasch M, Gratacós-Ginès J, Hernández-Évole H, Moreira R, Sehrawat T, Malhi H, Olivas P, Hernández-Gea V, Bataller R, Shah V, Kamath P, Ginès P, Pose E. Adding Inflammatory Markers and Refining National Institute on Alcohol Abuse and Alcoholism Criteria Improve Diagnostic Accuracy for Alcohol-associated Hepatitis. Clinical Gastroenterology And Hepatology 2023, 21: 3080-3088.e9. PMID: 37004974, DOI: 10.1016/j.cgh.2023.03.023.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisAlcohol-related liver diseaseAlcoholic steatohepatitisLiver biopsyDiagnostic accuracyLiver diseaseValidation cohortNIAAA criteriaAlcohol abuseSevere alcohol-associated hepatitisC-reactive proteinGold standardNational InstituteInflammatory markersConsecutive patientsDerivation cohortHistological diagnosisMayo ClinicHospital ClínicTherapeutic studiesAlcoholism criteriaClinical investigatorsConsensus criteriaAbstractTextNoninvasive diagnosis